The final analysis of Pfizer and BioNTech's COVID-19 clinical trial data demonstrates it is 95 percent effective and has consistent results across "age, gender, race and ethnicity demographics," which is a slight improvement over the interim data it announced on Nov. 9 showing the vaccine had an efficacy of more than 90 percent.The Wednesday morning statement said the Phase 3 study “has met all primary efficacy endpoints" and achieved the safety milestone required for the FDA's Emergency Use Authorization, which they plan to submit a request for "within days.""To date, no serious safety concerns related to the vaccine candidate have...